Page 186 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 6
184
Table 1. Cost and probability parameters used in the cost analysis
Probabilities and other parameters Variable
Baseline value
Standard errora
Sensitivity rangeb
Reference
Frequency DPYD genotype DPYD wild-type DPYD variant allele carrier
0.9229 0.0771
0.0080 0.0080
Fixed 0.0617─0.0925
This study11 This study11
Risk severe toxicity
0.2269 0.3882 0.5015
Fixed 0.0526 0.0274
Fixed 0.3106─0.4658 0.4012─0.6018
This study11 This study11 Meta-analysis8
DPYD wild-type DPYD variant allele carrier, reduced dose
DPYD variant allele carrier, standard dose
DPYD wild-type Hospitalization nursing ward
0.1356 7.9855 0.0088 3.1111
Fixed Fixed Fixed Fixed
Fixed Fixed Fixed Fixed
This study11 This study11 This study11 This study11
Mean duration (days) Hospitalization ICU Mean duration (days)
DPYD variant allele carrier, reduced dose
0.1318─0.1976 4.6286─6.9428 0.0188─0.0282 0.8000─1.2000
Hospitalization nursing ward Mean duration (days) Hospitalization ICU Mean duration (days)
0.1647 5.7857 0.0235 1.0000
0.0400 1.3350 0.0163 0.1000
This study11 This study11 This study11 This study11
DPYD variant allele carrier, standard dose Hospitalization nursing ward
0.2350 13.1000 0.0310 7.0000
0.0422 3.0000 0.0172 3.0000
0.1880─0.2820 10.4800─15.7200 0.0248─0.0372 5.6000─8.4000
Analysis on previous study10,20 Analysis on previous study10,20 Analysis on previous study10,20 Analysis on previous study10,20
Mean duration (days) Hospitalization ICU Mean duration (days) Mean number of cycles
4.0166─6.0250 4.0341─6.0511
This study11 This study11
Capecitabine 5-FU
5.0208 5.0426
0.1567 0.3639
Type of fluoropyrimidine drug
This study11 This study11
Capecitabine 5-FU
0.83 0.17
Fixed Fixed
Fixed Fixed
Mean dose intensity for DPYD variant allele carriers
0.6910
0.0124
0.5528─0.8292
This study11
table continues